AIM/CREO (AIM/CREO)

London Stock Exchange AIM: AIM/CREO · GBX

GBX 11.5

+0.20 (+1.8%)· Recorded snapshot

Market cap	50.4M
Revenue (ttm)	7M
Net income (ttm)	-20.1M
EPS (ttm)	-GBX 0.05
Shares out	448.3M
Volume	231,315
Beta	0.96

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 7M
Net income (ttm): -20.1M
EPS (ttm): -GBX 0.05
Market cap: 50.4M

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-29.1

P25 n/aP50 n/aP75 n/a

ROIC-39.2

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All AIM/CREO indicators

Market & fundamental data

Available fields

186

Groups with data

Currency

GBP

Showing 186 of 186 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	GBP
Country	United Kingdom
Country code	UK
Earnings date	2026-12-23
Employees	104
Employees change	-25
Employees growth	-19.38%
Enterprise value	GBX 46.9M
Exchange	London Stock Exchange AIM
Financial currency	GBP
Financial report date	2026-06-30
First seen	2026-05-10
Fiscal year end	December
Founded	2003
Industry	Medical Devices
Is primary listing	Yes
ISIN number	GB00BZ1BLL44
Last earnings date	2025-12-23
Last refreshed	2026-10-28
Market cap	GBX 50.4M
Next earnings date	2026-12-23
Price	GBX 11.45
Price currency	GBX
Sector	Healthcare
SIC code	3845
Stock price date	2026-10-28
Symbol	aim/CREO
Website	https://www.creomedical.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-45.73%
EV/Sales	6.7x
FCF / EV yield	-46.45%
FCF yield	-43.23%
Industry forward P/E	13.68x
Industry P/E	21.46x
P/B ratio	1.05x
P/S ratio	7.2x
Price / tangible book value	1.08x
Sector forward P/E	14.52x
Sector P/E	22.58x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	-250%
EBITDA margin	-241.43%
Gross margin	41.43%
Operating margin	-250%
Pretax margin	-227.14%
Profit margin	-287.14%
Profit per employee	GBX -193,269
Profitable years	1
Revenue per employee	GBX 67,308
ROA	-17.42%
ROA (5Y)	-21.36%
ROCE	-35.71%
ROE	-29.15%
ROE (5Y)	-43.15%
ROIC	-39.15%
SBC / revenue	18.57%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	1
Gross profit growth	45%
Gross profit growth (Q)	50%
Gross profit growth 3Y	-39.66%
Gross profit growth 5Y	-6.39%
Net income growth years	1
Revenue growth	62.79%
Revenue growth (Q)	45.46%
Revenue growth 3Y	-36.39%
Revenue growth 5Y	-5.78%
Revenue growth quarters	1
Revenue growth years	1

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	GBX 200,000
Depreciation and amortization	GBX 600,000
EBIT	GBX -17.5M
EBITDA	GBX -16.9M
EPS	GBX -0.05
FCF per share	GBX -0.05
Financing cash flow	GBX 4.7M
Free cash flow	GBX -21.8M
Free cash flow minus SBC	GBX -23.1M
Gross profit	GBX 2.9M
Investing cash flow	GBX 500,000
Net borrowing	GBX -200,000
Net cash flow	GBX -13.1M
Net income	GBX -20.1M
Operating cash flow minus SBC	GBX -23.1M
Operating income	GBX -17.5M
Revenue	GBX 7M
Stock-based compensation	GBX 1.3M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-1.33
Book value per share	GBX 0.12
Debt / equity	0.08
Interest coverage	-43.75
Long-term assets	GBX 35M
Long-term liabilities	GBX 800,000
Net cash (debt)	GBX 3.5M
Net cash / market cap	6.94%
Net cash growth	-78.53%
Net debt / equity	-0.07
Piotroski F-Score	2
Property, plant and equipment	GBX 3M
Shareholders' equity	GBX 48.2M
Tangible book value	GBX 46.6M
Tangible book value per share	GBX 0.11
Total assets	GBX 56.8M
Total cash	GBX 7.4M
Total debt	GBX 3.9M
Total liabilities	GBX 8.6M
WACC	9.45%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.11
Current assets	GBX 21.8M
Current liabilities	GBX 7.8M
Current ratio	2.79
Inventory turnover	1.61
Net working capital	GBX 9.7M
Quick ratio	2.33
Working capital	GBX 14M
Working capital turnover	0.35

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-8.59%
Shareholder yield	-8.59%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	GBX 12.60
1D price change	1.78%
1M price change	-6.53%
1M total return	-6.53%
1W price change	6.51%
1W total return	6.51%
1Y price change	2.92%
1Y return CAGR	2.92%
1Y total return	2.92%
20-day SMA	GBX 10.61
200-day SMA	GBX 13.06
3M price change	-16.73%
3M total return	-16.73%
3Y price change	-65.04%
3Y return CAGR	-29.55%
3Y total return	-65.04%
50-day SMA	GBX 11.74
50-day SMA vs 200-day SMA	50under200
52-week high	GBX 18.50
52-week high date	2026-02-05
52-week low	GBX 9.50
52-week low date	2026-10-05
5Y price change	-92.84%
5Y return CAGR	-40.99%
5Y total return	-92.84%
6M price change	-5.57%
6M total return	-5.57%
All-time high	GBX 250.00
All-time high date	2018-10-02
All-time low	GBX 9.22
All-time low date	2025-04-23
Average true range (ATR)	GBX 0.51
Average volume	776.4K
Beta (1Y)	1.55
Beta (2Y)	0.97
Beta (5Y)	0.96
Change from 52-week high	-38.11%
Change from 52-week low	20.53%
Change from all-time high	-95.42%
Change from all-time low	24.17%
Change from open	0.62%
Day's gap	1.16%
Dollar volume	GBX 2.6M
High price	GBX 11.50
Low price	GBX 11.19
Monthly RSI	37.98
Open price	GBX 11.38
Position in 52-week range	83.87%
Previous close	GBX 11.25
Price vs 150-day SMA	-9.15%
Price vs 20-day SMA	7.97%
Price vs 200-day SMA	-12.3%
Price vs 50-day SMA	-2.45%
Relative volume	0.3
RSI	53.73
Sharpe ratio	0.18
Sharpe ratio (3Y)	-0.51
Sharpe ratio (5Y)	-0.72
Sortino ratio	0.48
Sortino ratio (3Y)	-0.7
Sortino ratio (5Y)	-1.15
Volume	231.3K
Weekly RSI	43.14
YTD price change	15.66%
YTD total return	15.66%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	409.7M
Shares change (YoY)	8.59%
Shares held by insiders	3.21%
Shares held by institutions	76.01%
Shares outstanding	448.3M

Deeper analysis on AIM/CREO

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this AIM/CREO report

Is a complete AIM/CREO research report available?

No complete published report is available for aim/CREO (AIM/CREO) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

AIM/CREO (AIM/CREO)

Price

Financial snapshot

Fair-value bridge

Latest news · AIM/CREO

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All AIM/CREO indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on AIM/CREO

Frequently asked questions